Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
rabphilin-3A CRISPR/Cas9 KO Plasmid (h): sc-404628
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- rabphilin-3A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the rabphilin-3A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: rabphilin-3A Antibody (D-6): sc-393197
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
rabphilin-3A CRISPR/Cas9 KO Plasmid (h) | sc-404628 | 20 µg | $397.00 |
Overview
RPH3A encodes rabphilin-3A, a Rab3A/Rab27 effector enriched in neurons that couples Ca²⁺-dependent signaling to regulated vesicle exocytosis. Through interactions with small GTPases and synaptic vesicle components, rabphilin-3A contributes to vesicle docking, priming, and release probability, supporting efficient neurotransmitter secretion. Its activity intersects with presynaptic membrane trafficking pathways and cytoskeletal dynamics that coordinate vesicle recycling and synaptic plasticity. Dysregulation of synaptic vesicle transport and release machinery involving RPH3A is relevant to mechanistic studies of neurological and neuropsychiatric disease biology.
rabphilin-3A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RPH3A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RPH3A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RPH3A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish rabphilin-3A protein expression.
This CRISPR knockout system enables efficient generation of RPH3A-deficient cell models for investigation of rabphilin-3A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RPH3A exon(s) critical for rabphilin-3A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RPH3A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by rabphilin-3A CRISPR/Cas9 KO Plasmid (h) and rabphilin-3A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RPH3A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by rabphilin-3A HDR Plasmid (h) and rabphilin-3A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RPH3A homology arms to support homology-directed repair at defined RPH3A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.